We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Comment & Response |

IgG4-Related Skin Disease

Julia S. Lehman, MD1,2; Mark R. Pittelkow, MD1; Thomas C. Smyrk, MD2
[+] Author Affiliations
1Department of Dermatology, Mayo Clinic, Rochester, Minnesota
2Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota
JAMA Dermatol. 2013;149(12):1439-1440. doi:10.1001/jamadermatol.2013.7326.
Text Size: A A A
Published online


To the Editor We read with interest the article recently published in JAMA Dermatology that reported successful treatment of IgG4-related disease (IgG4-RD) of the skin with thalidomide.1 A recently described disease entity, IgG4-RD can affect virtually any organ of the body, and while skin involvement is rare, it may manifest clinically as nonspecific skin papules, plaques, and nodules.2 Ingen-Housz-Oro et al1 rendered a diagnosis of IgG4-RD in the skin of 2 patients with skin nodules based on evaluation of skin biopsy specimens showing dense lymphocytic infiltrates with lymphoid follicles, dermal fibrosis, and a IgG4 to IgG ratio exceeding 75%. Although these patients may indeed have had isolated skin involvement by IgG4-RD, we highlight herein recent advances in the diagnosis of IgG4-RD to emphasize the importance of correlating clinical features, histopathologic evidence, and immunophenotypic data derived from careful interpretation of IgG4 and IgG stains.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





December 1, 2013
Saskia Ingen-Housz-Oro, MD; Nicolas Ortonne, MD, PhD; Olivier Chosidow, MD, PhD
1Department of Dermatology, Henri Mondor Hospital, Créteil, France
2Department of Pathology, Henri Mondor Hospital, Créteil, France
JAMA Dermatol. 2013;149(12):1440. doi:10.1001/jamadermatol.2013.7329.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

4 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...